A Case of Resistance to Selective RET-TKI Therapy With Pleural-Genotyped MET Amplification and Response to Crizotinib

Clinical Practice Points•RET (rearranged during transfection) gene rearrangements have provided a viable therapeutic target for oncologic treatment.•The mechanisms of resistance in non–small-cell lung cancer to highly selective RET inhibitors have not been fully described.•MET (mesenchymal to epithelial transition) amplification could induce resistance to highly selective RET inhibitors in patients with non–small-cell lung cancer. •RET...